Award
National Cancer Institute 5R01CA289629-02
Targeting anoctamin 6 to disrupt trogocytosis of cancer-associated fibroblasts
Recipient
Research Institute of Fox Chase Cancer Center
Award Amount
$642,755.00
Ceiling
$642,755.00
Awarded
February 25, 2026
Identifier
5R01CA289629-02
NIH/NCI awarded a research grant to study the role of ANO6 in cancer-associated fibroblasts to disrupt lipid transfer to pancreatic tumor cells, aiming to inhibit tumor growth and enhance immune response.
Description
This is a research project funded by NIH/NCI focusing on pancreatic cancer immunotherapy and tumor microenvironment targeting ANO6 in CAFs. The project investigates ANO6, a phospholipid scramblase expressed in cancer-associated fibroblasts (CAFs), which is critical for trogocytosis—a process where CAFs transfer lipids directly to tumor cells. The research aims to determine how ANO6 activity is regulated, how its blockade can prevent CAF trogocytosis and tumor growth, and whether inhibiting ANO6 can enhance anti-PDAC immunity.